Lipid-lowering drugs and cancer: an updated perspective.
Azin AlizadehaslMaryam Sadat AlaviShabnam BoudaghMohaddeseh Sadat AlaviSomaye MohebiLeila AliabadiMahsa AkbarianParisa AhmadiMassimo R MannarinoAmir Hossein SahebkarPublished in: Pharmacological reports : PR (2023)
Statins and non-statin medications used for the management of dyslipidemia have been shown to possess antitumor properties. Since the use of these drugs has steadily increased over the past decades, more knowledge is required about their relationship with cancer. Lipid-lowering agents are heterogeneous compounds; therefore, it remains to be revealed whether anticancer potential is a class effect or related to them all. Here, we reviewed the literature on the influence of lipid-lowering medications on various types of cancer during development or metastasis. We also elaborated on the underlying mechanisms associated with the anticancer effects of antihyperlipidemic agents by linking the reported in vivo and in vitro studies.